Skip to content

Veradermics MANE Free cash flow

Free cash flow at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$1.47B-56.6%
Organon logo
OrganonOGN
$188M+337%
PTH
Pelthos Therapeutics Inc.PTHS
-$13.32M-2,008%
Pulse Biosciences, Inc. logo
Pulse Biosciences, Inc.PLSE
-$14.63M-7.8%
Hims & Hers Health logo
Hims & Hers HealthHIMS
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS

Other financials

Income statement

See full
Operating income-$29.9M-131%
Net income-$27.2M-120%
EPS (diluted)-$1.32+93.3%

Balance sheet

See full
Cash & equivalents$168.4M+419%
Total debt$4.0K
Total equity$390.6M+744%
Total assets$397.4M

Cash flow

See full
Operating cash flow-$21.2M-59.0%
CapEx--100%

Valuation

See full
Market cap$5.22B+315%

Returns & leverage

See full
Return on equity-28.7%
Current ratio59.1×

Where this comes from

Calculated from Veradermics ’s reported figures.

The official record: Veradermics ’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Veradermics 's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Veradermics 's free cash flow?
Veradermics (MANE) reported free cash flow of -$21.17M in Q1 2026.
How has Veradermics 's free cash flow changed year-over-year?
Veradermics 's free cash flow decreased by 58.7% year-over-year, from -$13.34M to -$21.17M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.